Compounds > 9-(4'-aminophenyl)-9h-pyrido(3,4-b)indole
Page last updated: 2024-12-08

9-(4'-aminophenyl)-9h-pyrido(3,4-b)indole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID154224
SCHEMBL ID15263336
MeSH IDM0379952

Synonyms (22)

Synonym
benzenamine, 4-(9h-pyrido(3,4-b)indol-9-yl)-
ccris 9009
4-(9h-pyrido(3,4-b)indol-9-yl)benzenamine
aminophenylnorharman
apnh cpd
9-(4'-aminophenyl)-9h-pyrido(3,4-b)indole
4-pyrido[3,4-b]indol-9-ylaniline
FT-0662021
nmc04j95oa ,
219959-86-1
unii-nmc04j95oa
9-(4'-aminophenyl)-9h-pyrido[3,4-b]indole
SCHEMBL15263336
4-(beta-carboline-9-yl)aniline
4-(9h-pyrido(3,4-b)indole-9-yl)aniline
4-(9h-.beta.-carbolin-9-yl)aniline
j1.034.926e ,
DTXSID70176423
AKOS030255864
J-014402
Q27284949
4-(9h-pyrido[3,4-b]indol-9-yl)aniline

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No toxic changes were observed in Leydig cells under these conditions and serum follicle-stimulating hormone and luteinizing hormone concentrations were also unchanged from control values."( Testicular toxicity in F344 rats by aminophenylnorharman, formed from norharman and aniline.
Hisada, S; Ishihara, J; Kawamori, T; Mitsumori, K; Sugimura, T; Totsuka, Y; Wakabayashi, K, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.47 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (11.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
proadifen
Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.		2.0110diarylmethane
aniline
[no description available]		3.8110anilines;
primary arylamine
2-toluidine
2-toluidine: RN given refers to parent cpd. o-toluidine : An aminotoluene in which the amino substituent is ortho to the methyl group.		2.0310aminotoluenecarcinogenic agent
norharman
norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.		3.72100beta-carbolines;
mancude organic heterotricyclic parent		fungal metabolite;
marine metabolite
isoluminol
isoluminol: chemiluminescent label		2.0310
harmine
Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.		3.72100harmala alkaloidanti-HIV agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
metabolite
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		210organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
deoxyguanosine
[no description available]		210purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
guanosine
ribonucleoside : Any nucleoside where the sugar component is D-ribose.		2.0510guanosines;
purines D-ribonucleoside		fundamental metabolite
8-hydroxy-2'-deoxyguanosine
8-Hydroxy-2'-Deoxyguanosine: Common oxidized form of deoxyguanosine in which C-8 position of guanine base has a carbonyl group.. 8-hydroxy-2'-deoxyguanosine : Guanosine substituted at the purine 8-position by a hydroxy group. It is used as a biomarker of oxidative DNA damage.		210guanosinesbiomarker
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Colon
[description not available]		02.7130
Cancer of Liver
[description not available]		02.730
Colonic Neoplasms
Tumors or cancer of the COLON.		02.7130
Liver Neoplasms
Tumors or cancer of the LIVER.		02.730
Adenocarcinoma, Basal Cell
[description not available]		02.4320
Hepatocellular Carcinoma
[description not available]		02.0210
Leucocythaemia
[description not available]		02.0210
Cancer of the Thyroid
[description not available]		02.0210
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.4320
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0210
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		02.0210
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		02.0210
Experimental Hepatoma
[description not available]		02.0210
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Condition, Preneoplastic
[description not available]		0210
Precancerous Conditions
Pathological conditions that tend eventually to become malignant.		0210
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		0210
Abnormalities, Autosome
[description not available]		02.0110
Cleft Palate, Isolated
[description not available]		02.0110
Cleft Palate
Congenital fissure of the soft and/or hard palate, due to faulty fusion.		02.0110
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.0110